Bessemer Group’s Anavex Life Sciences AVXL Stock Holding History

Bessemer Group’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1	Closed	–	–	2487
2025 Q2	$0	Hold	1	–	–	﹤0.01%	2392
2025 Q1	$0	Buy	+1	New	+$9	﹤0.01%	2444

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bessemer Group's AVXL Position: Q3 2025 in Review

Bessemer Group sold out of Anavex Life Sciences (AVXL) in Q3 2025, closing a stake of 1 share.

Bessemer Group first reported a position in AVXL in Q1 2025 and held it in 2 quarters. The position peaked at $0 in Q2 2025. 186 funds tracked by Wall St. Rank hold AVXL as of Q3 2025.

Bessemer Group reported no remaining Anavex Life Sciences position as of Q3 2025 after selling out during the quarter.
Bessemer Group sold 1 Anavex Life Sciences share in Q3 2025.
Bessemer Group first reported a position in Anavex Life Sciences in Q1 2025 and held it in 2 quarters.
Bessemer Group's Anavex Life Sciences position peaked at $0 in Q2 2025.
186 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q3 2025.

Based on Bessemer Group's 13F filing for Q3 2025, filed 5 Nov 2025.